/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene
Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix · Oct 21, 2026

Addgene's Greg Crescenzi on scaling a trusted repository to speed science by removing sharing friction between academia and industry.

COVID proved industry access to academic reagents speeds solutions

Greg Crescenzi says 90% of Addgene's COVID deposits and resources were made available to industry during the pandemic, enabling a faster collective response. Addgene now wants to extend that same industry access to much of its other translational material, not just crisis-specific reagents, according to him.

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene thumbnail

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix·a month ago

Addgene's 15,000 CRISPR plasmids drove 300,000 shipments

Greg Crescenzi says Addgene has received over 15,000 CRISPR plasmid deposits, including foundational materials, and those have generated 300,000 shipments to 5,000 organizations. That shipment volume shows how a central repository prevents many labs from separately rebuilding the same validated tools and wasting time and money.

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene thumbnail

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix·a month ago

Addgene solved sharing by removing depositor burden

Malina Fan spent months trying to get plasmids, then realized depositing scientists wanted to share but lacked time and infrastructure. Greg Crescenzi says Addgene took over storage, logistics, legal agreements, QC, and curation, removing the burden from both requesters and institutions shipping materials so sharing could scale.

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene thumbnail

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix·a month ago

Addgene's success means academic-industry catalog line disappears

Greg Crescenzi defines success as materials, methods, and even results flowing freely by default between academia and industry. Restricting access should be a conscious exception, he says. He also wants industry to share unpublished experiment information, including failures, because that knowledge is valuable to others.

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene thumbnail

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix·a month ago

Addgene now wants industry tools shared back to academics

Greg Crescenzi says Addgene's Solid Bio deal brings a therapeutic company's technology to academic and industry labs. Addgene already sells NEB and Promega products and wants more such partnerships, making reagent sharing flow from industry to academia as well as the reverse, according to him.

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene thumbnail

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix·a month ago

Addgene's curated 20-year archive is an AI partnership asset

Greg Crescenzi says Addgene holds historical, curated information that no one else has and is talking with software and AI companies about partnerships. He sees AI today as rapidly changing the space and wants Addgene's archive to support new data and information products, he says.

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene thumbnail

Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

The BioHub - by Avetix·a month ago